Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, announced two poster presentations at The Liver Meeting® 2020, set for November 13-16, 2020. The presentations will showcase findings from the AXA1125-003 clinical study, focusing on subjects with type 2 diabetes and the overall study population.
Key abstracts include:
- 1663: Examining biological activity related to glucose and liver fat in NAFLD patients with type 2 diabetes.
- 1694: Safety and biological activity of AXA1125 and AXA1957 in NAFLD patients.
Axcella (Nasdaq: AXLA), a biotechnology company, announced a publication in iScience highlighting the potential of endogenous metabolic modulator (EMM) compositions to treat complex diseases. The publication discusses how EMMs like amino acids can address multiple biological pathways, providing safe, multifactorial treatments. Axcella's research indicates positive outcomes from five clinical studies targeting conditions like non-alcoholic steatohepatitis (NASH) and overt hepatic encephalopathy (OHE). The company aims to further advance its candidates into later-stage clinical trials.
Axcella (Nasdaq: AXLA) announced participation in a fireside chat at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 1:30 p.m. ET. The discussion will be streamed live on the company’s website, with a replay available for 30 days post-event. Axcella is focusing on developing innovative treatments using endogenous metabolic modulator compositions for complex diseases, particularly targeting non-alcoholic steatohepatitis (NASH) and reducing the risk of overt hepatic encephalopathy recurrence. For more details, visit www.axcellahealth.com.